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Transcriptional regulation of the plasminogen activator inhibitor type-2 (PAI-2) gene appears t o be an important factor in the response of mononuclear phagocytes t o inflammation. We have investigated here the molecular basis for PAI-2 synthesis in monocytic cells by reporter gene deletion analysis. A DNA fragment containing 5.1 kb of 5' flanking region through t o the start of the second exon was fused t o a chloramphenicol acetyl transferase (CAT) reporter gene, transfected into macrophage and nonmacrophage cells and tested for PAI-2 promoter-directed CAT activity in the presence and absence of phorbol ester. Deletion analysis showed the existence of three major transcription regulatory regions. (1) A positive regulatory region contained in the proximal promoter mediates basal transcription and 12-phorbol 13-myristate acetate inducibility. (2) A negative regulatory region, or silencer, present between -1977 and -1675, was found t o repress PAL2 promoter activity in an orientation-ONONUCLEAR phagocytes are key regulators of in-M flammatory and immune responses. A protein that has the potential to significantly influence the biological response of the monocyte in an inflammatory situation is plasminogen activator inhibitor type-2 (PAI-2). PAI-2 is a member of the family of serine proteinase inhibitors or serpins that are a large, structurally conserved family of proteins that regulate processes as diverse as blood coagulation, fibrinolysis, inflammation, cancer development, and neurology. The increasing number of pathologic conditions that result from acquired deficiencies and genetic abnormalities in members of this family highlight their importance to many cellular functions and biological systems. ' The characteristics of PAI-2 suggest that it may be a key biological regulator of several macrophage functions. PAI-2 is a potent inhibitor of urokinase-type plasminogen activator (uPA)*.~ and, as such, plays an essential role in regulating uPA-initiated proteolysis4 that occurs during migration of macrophages to various targets such as inflammatory sites. However, the role of PAI-2 does not appear to be limited by its ability to inhibit plasminogen activation, because our work' and that of others6,' shows that PAI-2 expression is associated with the regulation of cell death. Expression of and position-independent manner, but not in a cell-specific manner. (3) A second positive regulatory element, located upstream between approximately -5100 and -3300, appears t o overcome inhibition mediated b y the silencer in a cell-specific manner, suggesting a mechanism for the regulation of this gene. We have localized the motif responsible for silencer activity t o a 28-bp DNA sequence containing a unique 12-bp palindrome centered at an Xba I restriction enzyme site, CTCTCTAGAGAG, which is designated the PAI-2-upstream silencer element-I (PAUSE-1 1. This element binds a specific PAUSE-1 binding factor as determined by mobility shift analysis. We conclude that P A M gene transcription is regulated by both positive and negative control mechanisms that may be important for the regulation of other genes as well.
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PAI-2 inhibits tumor necrosis factor a (TNF)-induced apoptosis',6 and prevents programmed cell death of human macrophages infected with Mycobacterium avium. ' The data suggest that PAI-2 may inactivate one of the serine proteinases implicated in a cell death pathway. ' PAI-2 synthesis is rapid and strong in response to inflammatory stimuli including interleukin-1 p,* TNF,9 lipopolysaccharide," and native and modified low-density lipoprotein" in monocytes. TNF is the major cytokine effector for the induction of septic shock and for most inflammatory and cell-mediated immune reactions. The synthesis of PAI-2 by monocytes after endotoxin or TNF stimulation may inhibit plasminogen activation, thus facilitating the deposition of fibrin. Furthermore, the synthesis of PAI-2 may inhibit or delay macrophage cell death due to the cytolytic effects of TNF in an inflammatory environment.s These activities are particularly relevant in sepsis'' and in advanced myelomonocytic leukaemias (M4 and M5)" in which PAI-2 synthesis is markedly elevated. In vivo, the PAI-2 gene is expressed primarily in activated monocytes and macrophages," in placental trophoblast^,'^ and in differentiated keratinocytes," although a greater number of cell-types may be induced to synthesise PAI-2 in vitro." The dual functionality of PAI-2 and its relatively restricted patterns of expression suggest a high degree of specificity for PAI-2 synthesis and the involvement of critical regulatory pathways and factors for controlled expression of this gene. It is not known whether the general absence of PAI-2 gene expression in many cells and tissues is the result of active or passive mechanisms affecting gene transcription. We have previously investigated the mechanisms involved in the regulation of PAI-2 gene expression in monocytic cells. Nuclear run-on transcription assays show that the synthesis of PAI-2 mRNA in both U937 and HL60 monocytic cells is controlled at the transcriptional l e~e l ' '~~* and is independent of ongoing protein synthesis." The 5' proximal flanking region of the PAI-2 gene contains DNA sequence elements that are clearly involved in PAL2 gene transcnp-tion, including a TATA box (TATAAA) located 31 bp upstream of the transcription initiation site (tis), three AP-1 sites, two AP-2 sites, and a CAMP-responsive element (CRE) located between -544 and -97.'' A retinoic acid response element has been identified further upstream at -1659." Southwestern blotting data implicate additional regulatory elements upstream and downstream of the proximal promoter region that may control cell-type-specific gene expression" and in particular, its synthesis in monocytic cells. In the present report, reporter gene deletion analysis is used to identify functional elements in the PAI-2 gene responsible for the differential synthesis of PAI-2 in (1) the monocytelike U937 cell that constitutively expresses low to negligible levels of PAI-2, but in which PAI-2 is induced in response to the differentiating agent" 12-phorbol 13-myristate acetate (PMA); and (2) the HeLa cell, a cervical carcinoma that does not synthesise PAI-2 either constitutively or in response to inducing agents. The results show the involvement of a silencer and an antisilencer or transactivating element in the regulatory mechanism. Localization of the silencer shows a novel palindromic sequence motif important for repression of transcription, which we have designated the PAI-2 upstream silencer element-1 (PAUSE-1).
MATERIALS AND METHODS
The human macrophage-like U937 cell line, the monocyte-like RC2A leukemic cell line, the epithelial-like HeLa cell line, and the fibrosarcoma cell HT1080 were obtained from the American Type Culture Collection (Rockville, MD). The mature human macrophage cell line, M0noMac6:~ was kindly provided by Dr H.W.L. Zeigler-Heitbrock (University of Munich, Munich, Germany). Cells were maintained in RPMI 1640 medium supplemented with 10% fetal calf serum and 2 mmoVL glutamate and incubated in 5% CO, and 95% air atmosphere at 37°C. Cell viability was determined by trypan blue dye exclusion. All cultures were checked routinely and determined to be mycoplasma-free. PMA was added at 40 ng/mL.
Standard techniques were used for all recombinant DNA manipulations." Isolation of the PAI-2 gene containing 5.1 kb of the 5' flanking region through to the start of the second exon (pBS8.8pro) is described elsewhere." An 8.8-kb EcoRVXba I DNA fragment spanning the region -5100 to +66 of the PAI-2 gene was inserted into the blunt-ended Sal I site of the promoter-less chloramphenicol acetyltransferase (CAT) vector, pCATBasic (Promega, Madison, WI), to yield the longest reprter construct (8.8 kb), which was designated pCAT5'-5.1. Subsequent 5' deletions were generated by inserting the 7.2-kb HindIII fragment of pBS8.8pro into the Cla I site of pGEM-7Zf (Promega), followed by excision with EcoRZIHindIII into the blunt-ended Sal I site of pCATBasic. A series of deletions from the 5' end were generated after digestion with Kpn I and Sma I and treatment with exonuclease IIUmung bean nuclease for various times. 25 The resulting mutant constructs were characterized by DNA sequence analysis. The numbering system used for the PAI-2 promoter sequence is based on transcription initiating at C in position -1, as reportedz6 and independently confirmed (T.M. Antalis, unpublished data).
Cells were transfected by electroporation using conditions optimized for each cell line. Generally, cells (5 X 10') in log phase were electroporated at 250 mV, 960 mF using a Bio-Rad Gene Pulser with Capacitance Extender (BiobRad, Hercules, CA) in the presence of 20 pg of plasmid DNA, unless otherwise specified. All plasmid DNA preparations Cell culture.
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Transient transfections and CAT assays.
used for electroporation were CsCl gradient purified. Plasmid DNAs included a series of PAI-2 promoter-CAT mutant constructs, a promoter-less CAT negative control, and positive controls consisting of the @actin promoter (4.3-kb EcoRI-Alu I DNA fragment) fused to the CAT reporter gene (p,8ACAT)" and pCAT-Control (Promega), a construct that contains the CAT reporter gene driven by the SV40 promoter and enhancer. Electroporated cells were diluted into 5 mL RPMI 1640 and 10% fetal calf serum and allowed to incubate for 20 to 24 hours in the presence or absence of 40 ng/mL PMA. Cells were harvested and cell extracts were assayed for CAT activity as described.28 CAT activity was monitored by quantitation of signals from thin-layer chromatographs using a Molecular Dynamics Phosphorimager and analyzed using ImageQuant software (Molecular Dynamics, Sunnyvale, CA). CAT activity was standardized to the protein concentration of the cell pool as determined by Bio-Rad protein assay using bovine y-globulin as the protein standard. To compare CAT conversion values between several independent experiments and between different cell lines, the CAT activity in each experiment was normalized relative to the CAT activity of an identical cell pool transfected with a positive control plasmid (,&actin CAT or pCAT-Control).
The The constructs containing mutations in the 12-bp Xba I palindrome sequence were constructed as follows: pCATSf-l.9Xba. was generated by linearizing pCAT5'-1.9 with Xba I, endfilling to destroy the restriction enzyme site, and religating the resultant blunt ends with T4 DNA ligase. pCAT5'-1.7 + 350lCATTAG was generated using a PCR-based overlap extension strategy to mutate the central bases in the Xba I palindrome, TCTAGA, to the sequence CATTAG, as described below. The following synthesized 28-mer CA'ITAG oligonucleotides were used: CAlTAGF "GTATAGGGCCTCCAT-TAGGAGT'ITTAGC''; and CATTAGR: "GCTAAAACTCCT-AATGGAGGCCCTATAC". ForwardSup and CATTAGR primers and XbaFonvard and CATTAGF primers, respectively, were combined to generate DNA subfragments containing overlapping mutations within the 350-bp silencer element at the Xba I site. These DNA fragments were then combined and Forwardsup and Reversesup were used to generate a 350-bp DNA fragment containing
Construction of additional PAI-2 promoter mutants.
the desired mutation. This product was digested with EcoRV and cloned into the EcoRV site of pCAT5'-I .7 and the DNA sequence was verified.
Constructs containing subfragments of the 350-bp silencer fragment (pCAT5'-1.7 + 165, pCAT5'-1.7 + 175, pCAT5'-1.7 + 85, pCAT5'-1.7 + 90, pCAT5'-1.7 + 1 I I ) were generated by digestion of pBKS + 350 with EcoRV. Xba I, Spe I, andor Sau3A as required, endfilling and cloning the released subfragments into the EcoRV site of pCAT5'-1.7. Sequence and orientation were verified by DNA sequence analysis.
pCAT5'-I .7 + PAUSE-I was generated by annealling synthesised single-stranded oligonucleotides containing the 12-bp Xba I palindromic region (PAUSE-I ) in equimolar amounts, endfilling using the Klenow fragment of DNA polymerase, and cloning into the EcoRV site of pCAT5'-I .7. The oligonucleotides used were as follows: XbaMain: "GTATAGGGCCTCTCTAGAGAGTTTTAGC": and XbaPri: "GCTAAAACTCTCTAGAG". U937 cells were transfected with plasmid DNA constructs described in the text and incubated in the presence of PMA (40 nglmL) for 6 hours, at which time cells were lysed and RNA was isolated using the method of Chomczynski and mmol/L EDTA, and IO mg tRNA) containing the "P-labeled probe.
Hybridization was performed at 55°C for 16 hours, after which the samples were digested with RNaseA and T, at 37°C for 60 minutes. Reactions were treated with proteinase K and 0.5% sodium dodecyl sulfate at 37°C for 30 minutes, extracted with phenokhloroform. and loaded on a 6% Tris-borateEDTA (TBE) acrylamidehrea gel.
For the probe, a 650-bp PCR-amplified DNA fragment containing the CAT cDNA sequence was subcloned into the Hind111 site of pBluescriptKS. The antisense RNA probe (873 nt) was generated by linearization of the plasmid with Kpn I and in vitro transcription using T7 polymerase in the presence of "P-UTP. A protected fragment of 753 bp would be predicted to be generated after RNase digestion of mRNA from PAL2 promoter expression constructs.
Hela and U937 cell nuclear protein extracts were prepared as described."'.'' HeLa cell nuclear extract was also commercially obtained (Promega). Binding reactions were performed at room temperature for 20 minutes with approximately 5 X IO' cpm of radiolabeled DNA, 4 pg poly(d1-dC), and 3 yg of nuclear protein in binding buffer (IO mmol/L Tris-HCI, pH 8.0. 0.1 mmol/L EDTA, IO mmol/L MgClz, 50 mmol/L NaCI. 200 pglmL bovine serum albumin, 2% glycerol, 1 mmol/L dithiothreitol). Double-stranded excised DNA fragments were radiolabeled by endfilling with the Klenow fragment of DNA polymerase in the presence of "P-dCTP. Synthesised single-stranded oligonucleotides (XbaMain and XbaPri, as described above) containing the 12-bp Xba I palindromic region (PAUSE-I) were annealed in equimolar amounts and radiolabeled by endfilling as described above. For competition experiments, excess unlabeled competitors were incubated with the crude extract in the presence of the radiolabeled probe at 0°C for 15 minutes. Cold competition was performed using annealed synthesized mutant oligonucleotides. The CATTAG competitor was generated using the 28-mer CAITAGF and CATTAGR mutant oligonucleotides described above. The other synthesized mutant oligonucleotides were as follows: Xba.F 'GTATAGGGCCTCTCTAGCTAGAGT-TITAGC?'; Xba.R: "GCTAAAACTCTAGCTAGAGAGGCCCTA-TAC"; AGTTF "GTATAGGGCCTCTCTAGAGTACACTAGC3'; and A G m : 'GCTAGTGTACTCTAGAGAGGCCCTATAC3'. DNA/ protein complexes were separated on a 5% nondenaturing polyacrylamide gel run at EDTA, pH 8.2 (TBE). Complexes containing oligonucleotide probes were detected by autoradiography after 16 hours of exposure.
RESULTS
The 5"-jlanking region of the PAI-2 gene contains cello p e specific regulatory elements. To analyze sequences that may be important for transcriptional regulation of PAI-2 gene expression, the 5'-flanking region of the PAL2 gene was isolated and 5.1 kb of DNA 5' to the PAL2 transcription initiation site through to the start of the second exon was ligated to the bacterial CAT reporter gene in the plasmid designated pCAT5'-5.1 (diagrammed in Fig 2A) . The promoter activity of pCAT5'-5.1 was compared after transient transfection into a range of cells, the monocyte-like U937 and RC2A cells, the macrophage-like MonoMac6 (MM6) cell, the epithelial HeLa cell, and the HT1080 fibrosarcoma cell, as shown in Fig 1. To control for differences in transfection efficiency between cell lines, CAT activity was normalized to the activity of a reference plasmid transfected into an identical cell pool. Transfection of pCAT5'-5.1 into the monocytic cell lines (U937, MM6, and RC2A) and the fibrosarcoma HT1080 cells resulted in a low basal level of CAT activity. This basal activity was induced from 2.6-fold to 5.5-fold in response to PMA in U937, MM6, and HT1080 cells and greater than IO-fold in RCZA cells in response to PMA. Similarly, basal levels of PAI-2 promoter-directed CAT activity were detected in HeLa cells, but CAT activity was not increased in response to PMA. We have previously showed by Northern blot analysis that, although PAL2 mRNA is not constitutively synthesized in substantial amounts by cells of the monocytic lineage, PAL2 mRNA is transiently induced in response to PMA in monocytic cells within 4 hours.'2 A similar PAI-2 mRNA induction profile is observed in HT1080 cells in response to PMA, with maximal levels found at approximately 8 hours, and PAL2 mRNA is not detected in HeLa cells either in the presence or absence of PMA (data not shown). Thus, the pattern of CAT reporter gene activity observed for the PAL2 promoter-CAT constructs mirrors the pattern of steady-state mRNA expression in these cells. These data show that the 8.8-kb 5"flanking region of the PAI-2 gene contained within pCAT5'-5.1 is likely to contain regulatory elements responsible for the observed cell-specific expression and PMA inducibility of the PAL2 gene.
Deletion analysis of 5. I-kb yanking sequence of the PAI-2 gene. To identify specific sequence elements that may be involved in regulating PAI-2 gene expression, a series of CAT constructs with serial deletions within the PAL2 5'-flanking region were generated by unidirectional exonuclease Ill digestion. As shown in Fig 2A, the deletions range from -5.1 kb 5' to the transcription initiation site of the PAL2 promoter to constructs that terminate within the first intron and are missing the transcription initiation site. Each construct was assayed for CAT activity in U937 cells in the presence and absence of PMA, and the data from these experiments are summarized in Fig 2B. The results showed that basal levels of CAT expression were obtained in untreated U937 cells throughout the range of PAL2 deletion constructs. After treatment with PMA, a stimulation of CAT activity was observed with the -0.9-to -5.1-kb constructs, indicating that PMA-responsive elements were present in all constructs and were thus likely to be located within the proximal region of the promoter 3' to the -907-bp end point of pCAT5'-0.9. The promoter-less constructs pCAT5' + 0. I and pCAT5' + 0.5 showed that sequences upstream of the transcription initiation site were required for induced CAT activity and that the CAT activity observed was unlikely due to possible cryptic promoter sequences contained within the first intron. The full-length pCATS"5.1 construct showed maximal PMA-inducible CAT activity. However, the constructs containing 5'-flanking sequences between approximately -1.7 and -3.3 showed marked repression of CAT activity, with PMA-inducible CAT activity again restored in pCAT5'-1.7 and in the subsequent shorter constructs, pCAT5'-1.3 and pCAT5'-0.9. These data suggest that a negative regulatory element exists upstream of pCAT5'-1.7 (position -1675) in the PAL2 5'-flanking sequence.
Comparison of PAI-2 promoter activity in PAI-2-producing and -nonproducing cells. To assess the activity of the PAL2 promoter in a different cell type that does not normally synthesise PAI-2, the deletion constructs were transiently transfected into HeLa cells and analyzed for CAT activity (Fig 2C) . The overall pattern of CAT activity observed for the series of deletion constructs was similar to that observed in U937 cells, with two important exceptions. Firstly, in contrast to U937 cells, the CAT activity observed for each of the PAL2 promoter deletion constructs was not significantly regulated by PMA in HeLa cells. The lack of PMA responsiveness in HeLa cells was consistent nonetheless with the absence of PAI-2 mRNA induction in these cells in response to PMA. Constitutive CAT activity in pCAT5'-1.7 and in constructs extending downstream of pCAT5'-1.7 was observed. However, constructs containing 5'-flanking sequences directly upstream of -1675 showed repression of CAT activity similar to that observed in U937 cells. Secondly, whereas pCAT constructs between and including -1.7 and -3.3 showed repression of CAT activity similar to that observed in U937 cells, the full-length pCAT5'-5.1 construct remained repressed in HeLa cells. This result suggests that the positive regulatory element present between approximately -3.3 and -5.1 shown in U937 cells is inactive in HeLa cells.
In summary, the deletion mutant data indicate that a negative regulatory element exists upstream of position -1675 (A-1977/-1675) that is functional both in the PAI-2-producing and -nonproducing cells examined. In the PAI-2-producing monocytic U937 cell, a positive cis-acting element upstream of approximately -3.3 kb selectively overcomes this inhibition. The negative regulatory element either is capable of overcoming or functions independently of transcriptional activation mediated through PMA, because it represses both constitutive-and PMA-induced reporter gene activities.
Addition of the negative regulatory element to a transcriptionally active deletion mutant suppresses transcription. To further characterize the negative regulatory element identified by deletion analysis, a 350-bp DNA fragment containing the region A-19771-1675 was isolated by PCR amplification using flanking oligonucleotide primers and inserted into the transcriptionally active deletion mutant, pCAT5'-1.7, at the EcoRV site located at position -1437, as shown in Fig 3A. The resultant forward orientation (pCAT5'-1.7 + 350B) and reverse orientation @CATS'-1.7 + 350A) constructs were transiently transfected into both U937 and HeLa cells along with control constructs. As shown in Fig 3B, both of the insertion constructs showed reduced CAT activity (2.5-to 6-fold) in both cell types relative to the parental plasmid in the presence and absence of PMA. Thus, the negative regulatory element functions in a different position and in both orientations, properties characteristic of a transcriptional silencer.3' Deletion of the negative regulatory element from a trunscriptionally repressed deletion mutant restores PAI-2 yromoter-directed CAT activity. A region extending from -1977 to -1437 containing the negative regulatory element was excised from the normally repressed deletion mutant pCAT5'-1.9, as diagrammed in Fig 3A. The resultant construct, pCAT5'-1.9d540, was transiently transfected into both U937 cells and HeLa cells along with control constructs. As shown in Fig 3B, the results demonstrated a substantial increase in CAT activity over the repressed parental plasmid, pCAT5'-l .9, but the CAT activities obtained with pCAT5'-I .7 were not attained. These data show that deletion of the silencer element is sufficient to restore PAI-2 promoter-directed gene activity, but sequences downstream of pCAT5'-1.7, specifically A-1675/-1437, may also contribute to the regulation of PAI-2 promoter activity.
RNase protection analysis of PA!-2 promoter activit?, in PMA-stimulated U937 cells. To determine whether the repression of CAT activity was the direct result of reduced PAL2 promoter-directed transcriptional activity, RNase protection experiments were performed using RNA isolated from PMA-stimulated U937 cells transiently transfected with the constructs pCAT5'-1.9, pCAT5'-1,9d540, pCAT5'-1.7, and pCAT5'-1.7 + 350B. tRNA was included as a negative control. The 873-bp riboprobe used in these experiments was designed to span the CAT reporter gene sequence and include additional vector sequences that would not be predicted to be present in the mRNA transcripts generated by the PAI-2 promoter/CAT constructs. As shown in Fig 3C, one major protected product was detected corresponding to the predicted size of 753 bp, with no other specific reproducible bands identified. The intensities of the protected products were consistent with the CAT activities assayed in parallel transfections for the respective constructs (data not shown), with pCAT5'-1.7 showing the maximum levels of CAT mRNA transcription. These results show that the silencer directly represses CAT reporter gene transcription consistent with the decreases monitored in CAT reporter gene activity.
The efSeect of the negative regulatory region (A-19771-1675) on a heterologous promoter. To determine whether the PAI-2 negative regulatory region can exert its effect on a heterologous promoter, a single copy of the 350-bp DNA fragment was inserted into the enhancer-less pCAT-Promoter (pSV40CAT) in two positions, a position upstream of the SV40 promoter (pSV40CAT + 350u) and a position downstream of the CAT reporter gene (pSV40CAT + 350d).
as diagrammed in Fig 4A. An additional construct containing two copies of the 350-bp fragment, one in each position, was also generated (pSV40CAT + 350du). All three constructs showed a marked (>80-fold) repression of SV40-directed CAT activity after transfection into PMA-stimulated U937 cells, as can be seen by the ''C-chloramphenicol acetylation pattern shown in Fig 4B. Transfection of these constructs into HeLa cells and assay of CAT activity also showed strong repression of SV40-directed CAT activity (> 10-fold), and these results are summarized in Fig 4C. Thus, the PAI-2 negative regulatory element can repress the basal activity of a strong heterologous constitutive promoter and functions as a silencer in a position-independent manner.
The PAI-2 silencer region (A-1977/-1675) contains POtential transcription .factor binding mot$. DNA sequence analysis of the termination positions of deletion mutants pCAT5'-1.9 and pCAT5'-1.7 showed a 303-bp sequence that is shown in Fig 5. Comparative analyses of this sequence with the Genbank transcription factor database showed no specific sequence identity with known silencer elements. However, the sequence was found to contain motifs corresponding to potential transcription factor binding sites, including an API-like element'4 at position -1894, two ATrich regions at positions -I805 and -1738, a motif homologous to the SV40 core enhancer at -1701 ,?S and a glucocorticoid receptor binding site at position -1701.36 In addition, a 12-bp palindromic sequence centered around the Xba I restriction enzyme site at position -I838 was identified.
Anal.vsis of subfragments of the 350-bp region for silencer activify. As a first step towards identifying functional sequence motifs within the PAL2 silencer and to determine whether the entire 350-bp region is required for silencer activity or whether subfragments spanning parts of this region may be sufficient for transcriptional repression, the several partial subfragments spanning the silencer region were individually introduced into the EcoRV site of the transcriptionally active pCATS'-I .7 construct, generating the con-+ 85, pCATS'-I .7 + 90, and pCAT5'-1.7 + 11 1. The positions of the subfragments contained in each construct with respect to the 350-bp region are given in Fig 6A. The constructs were transiently transfected into both U937 and HeLa cells along with control constructs and the extracts tested for CAT activity relative to pCAT5'-I .7. None of the constructs containing subfragments inhibited transcription (Fig 6B) . These results suggest that ( I ) regions spanning at least two subfragments are required for repression and/or (2) a region structs pCAT5'-1.7 + 165, pCAT5'-1.7 + 175, pCAT5'-l . between two subfragments (disrupted by restriction enzyme digestion) may be required for silencing activity. Identification of the PAI-2 upstream silencer element (PAUSE-]). A candidate intersubfragment region for silencer activity was present between the two largest fragments, 165 bp and 175 bp, because the smaller subfragments are contained within these two fragments. This region contains an Xba I restriction enzyme site within a 12-bp palindromic sequence that could potentially provide a binding site for a trans-acting transcription factor." To investigate whether this motif may be involved in silencing activity, two reporter plasmids were constructed containing different mutations within the 12-bp palindrome. The specific nucleotide changes are shown in Fig 5. sequence. As shown in Fig 6B, transfection of these constructs into both HeLa and U937 cells showed enhanced CAT activity relative to the CAT activity obtained with the repressed wild-type 350-bp fragment. These results suggest that PAI-2 silencer activity may involve the 12-bp palindromic motif centered at the Xha I site.
To determine directly whether the 12-bp palindromic motif was responsible for the silencer activity, a 28-bp fragment containing the 12-bp palindrome was inserted into the EcoRV site in pCAT5'-1.7 at position -1437, resulting in pCAT5'-1.7 + PAUSE-I. The PAUSE-I sequence is shown in Fig 7. pCAT5'-1.7 + PAUSE-I wa5 transiently transfected into both U937
and HeLa cells along with control constructs. As shown in Fig   6C, the presence of the inserted 28-bp DNA fragment represses PAL2 promoter-directed CAT activity to a similar extent as pCAT5'-1.7 + 350B. These results show that the 28-bp motif mediates transcriptional silencing of PAL2 promoter activity, and we have designated this element the PAL2 upstream silencer element-1, or PAUSE-1. PAUSE-1 is a target for a DNA binding factor. Because the functional reporter gene experiments show that the PAUSE-1 sequence is involved in PAI-2 silencing activity, we investigated whether this sequence could bind nuclear DNA binding factors. Gel mobility shift assays using a synthetic double-stranded oligonucleotide containing PAUSE-1 showed one shifted complex, as shown in Fig 7, indicating the presence of a DNA binding factor present in HeLa cell nuclear extracts. The specificity of this interaction was confirmed by the addition of 1,000-fold excess cold PAUSE-1, which effectively competed with the radiolabeled PAUSE-1 for complex formation. A double-stranded oligonucleotide containing the mutant sequence, CATTAG, did not compete with radiolabeled PAUSE-1 for binding, as shown in Fig 7,  indicating that the central 6 bases of the palindrome are likely to be important for factor binding. Two doublestranded oligonucleotides, one containing the Xba* mutation and the other containing a disruption of the proximal AG dinucleotide repeat, also did not compete with PAUSE-1 for binding, indicating that an intact palindrome, particularly the purine dinucleotide motif, is important for factor binding. These results show that PAUSE-1 is a target for a transacting factor that is likely to be involved in repression of PAI-2 promoter activity.
DISCUSSION
Silencing of gene expression plays an important role in the regulation of a number of eukaryotic genes. In this study, we investigated 8.8 kb of PAI-2 5' flanking sequence upstream of the first translated exon for functional regulatory elements important in the control of PAI-2 gene expression. This 8.8-kb sequence was sufficient to drive high expression of the CAT reporter gene in PAI-2-expressing, PMA-induced U937 monocytic cells and did not show appreciable activity in PAI-2-nonexpressing HeLa cells, suggesting that it contains the essential determinants for the observed restricted expression of PAI-2. Functional deletion studies showed the existence of a transcriptional silencer and two positive regulatory regions involved in the transcriptional regulation of the PAI-2 gene.
The first positive regulatory region was identified downstream of position -907 in the proximal promoter and contains elements important for PMA responsiveness of the PAI-2 promoter in U937 cells. Spanning the region -894 to -585 is an Alu repeat sequence. Although Alu repeat sequences may influence gene expression, the removal of this Alu repeat sequence has been shown in other cells to have no significant effect on the regulation of PAI-2 promoter a~tivity.~' The primary determinants important for responsiveness to PMA in HT1080 fibrosarcoma cells lie downstream of coordinate -585 and our data suggest that this is likely to be the case also for monocytic U937 cells. Specific elements likely to be involved are the CRE element at position -189 and an AP1-like site at position -103 that have been shown in HT1080 fibrosarcoma cells to be important for both basal and PMA-induced PAI-2 gene expres~ion.~~ However, in contrast, our data suggest that, in HeLa cells, these elements are controlled differently, because constructs containing sequences downstream of -1675 are not regulated by PMA but are constitutively active (see Fig 2) .
Upstream of position -894 in the PAI-2 5' flanking sequence exists a second Alu repeat sequence between -1387 and -1076 that does not appear to influence PAI-2 promoter activity (Fig 2) . However, further upstream, the region between position -1977 and -1675 defines a negative regulatory element that represses PAI-2 promoter activity in a cell-type-independent manner. Insertion of a DNA fragment containing A-1977/-1675 at an upstream position in a transcriptionally active PAL2 promoter deletion mutant was shown to repress CAT activity in an orientation-independent manner; conversely, deletion of a 540-bp region containing the silencer restored CAT activity.
The PAL2 negative regulatory region showed strong repression of the SV40 promoter in both U937 and HeLa cells. The repression was observed when the 350-bp region was placed in both upstream and downstream positions relative to the SV40 promoter. The level of inhibition observed with silencers in strong heterologous promoters can be dependent on the number of copies present, but we observe strong repression with a single copy of the 350-bp sequence. This region behaves as a silencer, an autonomous cis-acting negative regulatory element whose action is promoter, position. and orientation independent.33 PAL2 silencer activity is associated with a 30" region spanning positions A-I977/-1675 as defined by deletion studies. This region was found to contain binding sites for several DNA binding proteins as determined by mobility shift analyses (data not shown). However, one motif was shown to confer silencer activity when inserted into a transcriptionally active mutant. This motif contains a perfect 12-bp palindrome centered around an Xha I site at position -1832, termed PAUSE-l. The three repeated pyrimidine dinucleotide (CT) and the three repeated purine dinucleotide (AG) motifs within the CTCTCTAGAGAG palindrome are striking. The first half of the PAL2 silencer contains a region that shows 90% homology to the consensus silencer sequence S'-ANCCTCTCC/T-3' identified in cis-acting negative regulatory elements of other genes,37 whose members include human collagen type II,.'9 chicken lyso~yme,'~ rat osteocalcin.4" human &interferon:' and polyoma virus?'Sequence comparison of the PAL2 silencer with some of these negative regulatory elements is shown in PAUSE-1 is a site for a nuclear binding factor. Gel mobility shift analysis of the PAUSE-1 site. Labeled double-stranded oligonucleotide probes containing the PAUSE-1 sequence were incubated with 3 p g HeLa nuclear extract in the absence and presence of 1,000-fold excess double-stranded cold competitor. The arrow indicates the retarded PAUSE-1 binding factor complex.
bling of the 6 bases within the central core of the palindrome (TCTAGA to CATTAG) results in de-repression of promoter activity. suggesting that the CT triplet repeat in common with the other reported silencer elements may play a functional role in PAI-2 silencer activity. However, the PAI-2 silencer appears to be more complex in nature, because disruption of the palindrome by insertion of a CT directly after the AG within the central core de-represses promoter activity, indicating that the integrity of the AG triplet repeat is also important for silencer activity. Although several of the negative regulatory elements in other genes contain similar purine motifs followed by T repeats (underlined in Table I ), this DNA sequence appears to be unique to the PAI-2 gene.
An additional positive regulatory region was also identified further upstream of the silencer at A-S.lL3.3. This region contains an antisilencer activity or a transactivator that overcomes silencer-mediated repression in PAI-2-expressing U937 cells, but not in PAI-2-nonexpressing HeLa cells. It is of note that this rcgion contains DNA-protein binding sites previously targeted by Southwestern blot mapping.'' Silencers identified in eukaryotic genes are proposed to be involved in silencing gene expression in nonexpressing tissues.3'.'3 The results presented here provide the first demonstration that PAI-2 gene transcription is repressed in nonexpressing cells. They further provide the basis for a mechanism. which is diagrammed in Fig 8, effect of the negative factors bound to the silencer. This regulation could occur through several mechanisms, but may involve interactions between trans-acting factors associated with either the silencer or the proximal promoter region and the antisilencer element. In PAI-2-nonprcducing cells, these trans-acting factors would either not be present or be inactive, thus maintaining a repressed state. Thus, the PAI-2 silencer may be part of an efficient repression mechanism operative to restrict PAI-2 expression to specific cells. Although the proposed scheme fits with the available data, an assessment of these interactions will ultimately require the identification and characterization of the specific DNA binding factors that interact with these sequences.
This study clearly establishes that both positive and negative regulatory elements contribute to the control of PAI-2 gene transcription in monocytes. The identification of a transcriptional silencer in the PAI-2 gene may have important implications for inflammatory processes in which PAI-2-and uPA-mediated proteolysis play important roles. Future work will need to define other elements necessary for regulated gene expression and to characterize the cooperation betweeen the PAUSE-1 silencer and upstream elements involved in the control of transcription in monocytes. Definition of this regulatory mechanism may aid in the management of inflammatory diseases with modification of PAI-2 transcription through pharmacologic intervention and may also allow investigation of possible abnormal PAL2 gene regulation in disorders involving monocytes, such as myelomonocytic leukemias.
